Legal & General Group Plc lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 227.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 348,570 shares of the biopharmaceutical company’s stock after purchasing an additional 242,098 shares during the quarter. Legal & General Group Plc owned about 0.35% of Alnylam Pharmaceuticals worth $41,515,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth about $170,000. American International Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $255,000. Vident Investment Advisory LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $262,000. GSA Capital Partners LLP bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth about $306,000. Finally, IBM Retirement Fund bought a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth about $307,000. 90.21% of the stock is currently owned by hedge funds and other institutional investors.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 1,563 shares of the business’s stock in a transaction that occurred on Wednesday, June 20th. The stock was sold at an average price of $105.04, for a total transaction of $164,177.52. Following the completion of the transaction, the senior vice president now owns 16,063 shares in the company, valued at $1,687,257.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is owned by insiders.
Several equities research analysts have recently issued reports on the company. B. Riley reaffirmed a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, April 2nd. Piper Jaffray Companies reduced their target price on Alnylam Pharmaceuticals from $182.00 to $160.00 and set an “overweight” rating on the stock in a report on Wednesday. Zacks Investment Research raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. ValuEngine raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, BMO Capital Markets reduced their target price on Alnylam Pharmaceuticals from $160.00 to $134.00 and set an “outperform” rating on the stock in a report on Friday, May 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average price target of $139.33.
Shares of Alnylam Pharmaceuticals opened at $98.49 on Friday, according to Marketbeat. The company has a current ratio of 14.61, a quick ratio of 14.61 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals, Inc. has a 1-year low of $70.76 and a 1-year high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business had revenue of $21.90 million during the quarter, compared to analyst estimates of $35.23 million. During the same quarter in the previous year, the business earned ($1.25) earnings per share. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.82 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.